Drug Profile
Research programme: subtype-selective NMDA receptor modulators - Novartis
Latest Information Update: 01 Feb 2021
Price :
$50
*
At a glance
- Originator Jubilant Pharmaceuticals; Mnemosyne Pharmaceuticals
- Developer Novartis
- Class Neuropsychotherapeutics; Small molecules
- Mechanism of Action NMDA receptor modulators; NR2B N-Methyl D-Aspartate receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Alzheimer's disease; Attention-deficit hyperactivity disorder; Brain injuries; Schizophrenia; Stroke